The Zhongshan (CSTC) Biopharm Fund was established at the National Health Technology Park (NHTP) on December 19. Concurrently, an innovative drug investment forum was held.

In the second half of this year, the administrative committee of Zhongshan's Torch High-Tech Zone delegated the investment functions for the biopharmaceutical industry to the NHTP, which has been collaborating with provincial and municipal state-owned investment platforms, social investment institutions and leading park enterprises to jointly form an industrial fund cluster worth 1 billion yuan.

The Zhongshan (CSTC) Biopharm Fund represents another key component of the fund cluster. Jointly set up by NHTP, CSTC and the Zhongshan branch of China CITIC Bank, the fund aims to pool resources from governments, industries, and research, sci-tech and finance institutions. It will primarily focus on cutting-edge fields such as small nucleic acid drugs, next-gen targeted protein degradation technologies, novel oncolytic viruses, radiopharmaceuticals, and peptide drugs.